Should I buy or sell Evogene stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVGN shares. View EVGN analyst ratings or view top-rated stocks .

What is Evogene's stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Evogene's shares. Their EVGN share price targets range from C$4.00 to C$6.00. On average, they expect the company's stock price to reach C$5.00 in the next year. View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts .

How do I buy shares of Evogene?

Shares of EVGN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:EVGN

Evogene (EVGN) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free EVGN Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$5.00

Stock Analysis

Get Evogene alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Evogene Stock (TSE:EVGN)

Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

EVGN Stock News Headlines

April 16, 2024 | finance.yahoo.com

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

April 11, 2024 | finance.yahoo.com

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 7, 2024 | finanznachrichten.de

Kursverluste für das Wertpapier von Corteva (51,32 €)

March 9, 2024 | seekingalpha.com

Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript

March 7, 2024 | benzinga.com

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'

March 7, 2024 | washingtonpost.com

Evogene: Q4 Earnings Snapshot

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Evogene’s Growth Potential and Commercial Ramp-Up in 2024

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 22, 2024 | finanznachrichten.de

AgPlenus Ltd.: AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer

February 22, 2024 | finance.yahoo.com

AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer

February 20, 2024 | finance.yahoo.com

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide

February 20, 2024 | markets.businessinsider.com

Syngenta Crop, Lavie Bio Partner To Discover And Develop New Biological Insecticidal Solutions

January 17, 2024 | tmcnet.com

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

January 12, 2024 | finance.yahoo.com

Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy

December 21, 2023 | finance.yahoo.com

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

November 29, 2023 | finance.yahoo.com

Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' Now

November 14, 2023 | msn.com

Evogene Q3 2023 Earnings Preview

October 18, 2023 | finance.yahoo.com

Evogene Provides Operational Update Amidst Current Security Situation in Israel

October 14, 2023 | investing.com

Evergreen Fibreboard Bhd (EVGN)

October 10, 2023 | finanznachrichten.de

EVOGENE LTD

October 3, 2023 | msn.com

Alliance Global Partners Initiates Coverage of Evogene (EVGN) with Buy Recommendation

September 27, 2023 | finance.yahoo.com

Casterra Delivers First Shipment of Castor Seeds to Africa

September 21, 2023 | benzinga.com

Why Evogene Shares Are Moving

August 19, 2023 | msn.com

Lake Street Maintains Evogene (EVGN) Buy Recommendation

August 2, 2023 | msn.com

Evogene (EVGN) Price Target Increased by 166.67% to 4.08

July 19, 2023 | finance.yahoo.com

Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program

See More Headlines

Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Manufacturing
Industry: Pesticide & Other Agricultural Chemical Manufacturing
Sub-Industry: N/A
Current Symbol: TSE:EVGN
CUSIP: N/A
CIK: N/A
Web: www.evogene.com
Phone: N/A
Fax: N/A
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$5.00
High Stock Price Target: C$6.00
Low Stock Price Target: C$4.00
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Competitors

View All Competitors

EVGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Evogene stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings or view top-rated stocks.
What is Evogene's stock price target for 2024?: 2 Wall Street research analysts have issued 1-year price objectives for Evogene's shares. Their EVGN share price targets range from C$4.00 to C$6.00. On average, they expect the company's stock price to reach C$5.00 in the next year.
View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts.
How do I buy shares of Evogene?: Shares of EVGN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EVGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Evogene (EVGN) Stock Price, News & Analysis

About Evogene Stock (TSE:EVGN)

EVGN Stock News Headlines

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Competitors

EVGN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info